Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

depression

Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

ONLY AVAILABLE IN PAID PLANS.

Originally reported by rutlandherald. Read more

Source: https://www.rutlandherald.com/news/business/compass-pathways-successfully-achieves-primary-endpoint-in-second-phase-3-trial-evaluating-comp360-psilocybin-for/article_ead19db9-a312-5ef8-8c71-c465e5379762.html